Irene Cavros

Irene Cavros

Auto-generated profile, based on publicly available information

Irene Cavros

U.S. President’s Malaria Initiative, U.S. Centers for Disease Control and Prevention, Atlanta, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2025 in Malaria Journal
Verified
Journal Article
Open access
PDF file
ILIbrahim Maman Laminou
Ibrahim Maman Laminou
SKSanoussi Maman Kabirou
Sanoussi Maman Kabirou
IAIbrahima Issa Arzika
Ibrahima Issa Arzika
AYAbdou Yahaya
Abdou Yahaya
JAJehan Ahmed
Jehan Ahmed
ICIrene Cavros
Irene Cavros
Background: From August to October 2022, a therapeutic efficacy study of Niger’s first-line antimalarial, artemether-lumefantrine (AL), was conducted in four sites (Aderbissinat, Boboye, Aguié, and Baban Tabki) to evaluate its therapeutic efficacy and investigate for molecular markers of antimalarial drug resistance. Methods: Children aged 5 to 15 years old with uncomplicated malaria were assessed in a 28 day in vivo efficacy study. Genotyping using three markers ( msp1, msp2 and the PolyA microsatellite) and match counting using the WHO three-out-of-three algorithm, were used to distinguish recrudescences from new infections. A two-out-of-three algorithm was also utilized as a sensitivity analysis. Results: PCR uncorrected and corrected efficacy results at day 28 were calculated. Resistance markers were analysed by next-generation sequencing. Uncorrected treatment efficacies were 62.0% (95% CI 54–74) in Aderbissinat, 95.4% (95% CI 91–100) in Aguié, 98.7% (95% CI 96–100) in Boboye, and 50.6% (95% CI 42–62) in Baban Tabki. After PCR correction, AL efficacy was 100%, 97.5%, 100%, and 93.5%, respectively. Marker analysis revealed a high prevalence of S108N, C59R, and N51I mutations in the pfdhfr gene, and S436A and A437G mutations in the pfdhps gene. No validated or candidate pfkelch13 mutations were observed. Conclusion: In all four sites evaluated, AL retains therapeutic efficacies above the 90% WHO-recommended threshold using the primary three-out-of-three match criteria. In Aguié and Baban Tabki, efficacy remained above the threshold with certain match criteria and statistical approaches but fell below the cutoff using two-out-of-three matching and per-protocol methods, suggesting emerging efficacy concerns in southern parts of the country.

24 April 2026 in Malaria Journal
Verified
Journal Article
Open access
PDF file
ICIrene Cavros
Irene Cavros
AKAugustin Kpemasse
Augustin Kpemasse
AMAlexis Sacca Yarou Maye
Alexis Sacca Yarou Maye
RSRamani Saliou
Ramani Saliou
SKSakariahou Kpanou
Sakariahou Kpanou
AHAurore Ogouyemi Hounto
Aurore Ogouyemi Hounto
From June to December 2022, a therapeutic efficacy study of Benin’s first-line antimalarial, artemether-lumefantrine (AL), was conducted in three sit